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Following publication of the original article [1], we have
been alerted to errors in Figs. 2 and 8. In Fig. 2b, the
GAPDH loading control for Hec1A cells is shown twice
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(first column) the MAGE-A4 staining panel was re-
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Fig. 2 Regulation of L1CAM expression by epigenetic mechanisms. (a) RT-PCR analysis of cells treated for 5 days with the indicated concentration
of 5-AzaC, TSA or both compounds. DMSO was used as a mock control. Cells were lysed and mRNA was isolated and transcribed into cDNA. β-actin
served as internal standard. (b) Cells were treated as described above and cell lysates were prepared for Western blot analysis. MAb L1-11A was used
as a primary antibody followed by peroxidase conjugated Goat anti mouse IgG and ECL detection. (c) TSA and VA up-regulate L1CAM expression. Cells
were treated and analyzed as described in (b)
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Fig. 8 IHC analysis of testis and EC tissues. Expression of NY-ESO-1 and MAGE-A4 but absence of L1CAM in normal human testis tissue. Conversely,
L1CAM is expressed in type II EC but NY-ESO-1 and MAGE-A4 are undetectable. Note that a representative case of n = 5 is shown. Sequential tissue
sections were analysed by IHC
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